<div id="readability-page-1"><div><p><span>Arrowhead Pharmaceuticals Inc </span><span>:</span></p><ul><li>ARROWHEAD PHARMACEUTICALS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR PLOZASIRAN IN SEVERE HYPERTRIGLYCERIDEMIA</li><li>ARROWHEAD PHARMACEUTICALS - TO COMPLETE PHASE 3 STUDIES BY MID-2026</li><li>ARROWHEAD PHARMACEUTICALS: INTENDS TO SUBMIT A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO FDA BY YEAR-END 2026</li></ul></div></div>

ARWR

<p>Arrowhead Pharmaceuticals Inc :ARROWHEAD PHARMACEUTICALS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR PLOZASIRAN IN SEVERE HYPERTRIGLYCERIDEMIAARROWHEAD PHARMACEUTICALS - TO COMPLETE PHASE 3 STUDIES BY MID-2026ARROWHEAD PHARMACEUTICALS: INTENDS TO SUBMIT A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO FDA BY YEAR-END 2026</p>

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Plozasiran